Axa
VERA icon

Axa’s Vera Therapeutics VERA Stock Holding History

Axa’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-228,951
Closed -$5.39M – 983
2025
Q2 		$5.39M Sell
228,951
-16,614
-7% -$374K 0.02% 549
2025
Q1 		$5.9M Sell
245,565
-314
-0.1% -$10.1K 0.02% 506
2024
Q4 		$10.4M Sell
245,879
-390
-0.2% -$17.3K 0.03% 368
2024
Q3 		$10.9M Buy
246,269
+68
+0% +$2.58K 0.03% 382
2024
Q2 		$8.91M Sell
246,201
-25,877
-10% -$1.03M 0.03% 407
2024
Q1 		$11.7M Sell
272,078
-110,613
-29% -$3.94M 0.04% 384
2023
Q4 		$5.89M Buy
382,691
+111,698
+41% +$1.42M 0.02% 516
2023
Q3 		$3.72M Buy
+270,993
New +$4.65M 0.01% 594

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axa's VERA Position: Q3 2025 in Review

Axa sold out of Vera Therapeutics (VERA) in Q3 2025, closing a stake of 228,951 shares — an estimated $5.39M sold.

Axa first reported a position in VERA in Q3 2023 and held it in 8 quarters. The position peaked at $11.7M in Q1 2024. 175 funds tracked by Wall St. Rank hold VERA as of Q3 2025.

  • Axa reported no remaining Vera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Axa sold 228,951 Vera Therapeutics shares in Q3 2025, an estimated $5.39M.
  • Axa first reported a position in Vera Therapeutics in Q3 2023 and held it in 8 quarters.
  • Axa's Vera Therapeutics position peaked at $11.7M in Q1 2024.
  • 175 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.